EA201391406A1 - Лекарственные формы отамиксабана с улучшенной стабильностью - Google Patents

Лекарственные формы отамиксабана с улучшенной стабильностью

Info

Publication number
EA201391406A1
EA201391406A1 EA201391406A EA201391406A EA201391406A1 EA 201391406 A1 EA201391406 A1 EA 201391406A1 EA 201391406 A EA201391406 A EA 201391406A EA 201391406 A EA201391406 A EA 201391406A EA 201391406 A1 EA201391406 A1 EA 201391406A1
Authority
EA
Eurasian Patent Office
Prior art keywords
otamixaban
dosage forms
improved stability
amino
pharmaceutically acceptable
Prior art date
Application number
EA201391406A
Other languages
English (en)
Other versions
EA025572B1 (ru
Inventor
Вальтер Камм
Тилль Буссемер
Дорис Андерт
Бернд Кюн
Эрнст-Йозеф Тодт
Original Assignee
Санофи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи filed Critical Санофи
Publication of EA201391406A1 publication Critical patent/EA201391406A1/ru
Publication of EA025572B1 publication Critical patent/EA025572B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

Изобретение относится к фармацевтической композиции, содержащей метил (2R,3R)-2-{3-[амино(имино)метил]бензил}-3-{[4-(1-оксидопиридин-4-ил)бензоил]амино}бутаноат или его фармацевтически приемлемую соль и фармацевтически приемлемое кислотное реакционное соединение, или к водному раствору или дисперсии указанной композиции, а также к способу их получения, способам применения указанных композиций для лечения субъектов, страдающих от состояний, которые могут быть облегчены введением ингибитора фактора Ха.
EA201391406A 2011-03-29 2012-03-27 Лекарственные формы отамиксабана с улучшенной стабильностью EA025572B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11305347 2011-03-29
US201161499941P 2011-06-22 2011-06-22
PCT/EP2012/055361 WO2012130819A1 (en) 2011-03-29 2012-03-27 Otamixaban formulations with improved stability

Publications (2)

Publication Number Publication Date
EA201391406A1 true EA201391406A1 (ru) 2014-02-28
EA025572B1 EA025572B1 (ru) 2017-01-30

Family

ID=44584895

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391406A EA025572B1 (ru) 2011-03-29 2012-03-27 Лекарственные формы отамиксабана с улучшенной стабильностью

Country Status (18)

Country Link
US (3) US20140018398A1 (ru)
EP (1) EP2691075A1 (ru)
JP (1) JP5993933B2 (ru)
KR (1) KR101844623B1 (ru)
CN (1) CN103561723B (ru)
AR (1) AR085580A1 (ru)
AU (1) AU2012234323A1 (ru)
BR (1) BR112013024801A2 (ru)
CA (1) CA2830962C (ru)
CO (1) CO6801755A2 (ru)
EA (1) EA025572B1 (ru)
IL (1) IL228573A (ru)
MA (1) MA35050B1 (ru)
MX (1) MX342324B (ru)
SG (1) SG193932A1 (ru)
UY (1) UY33975A (ru)
WO (1) WO2012130819A1 (ru)
ZA (1) ZA201308061B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101844623B1 (ko) 2011-03-29 2018-04-02 사노피 안정성이 향상된 오타믹사반 제제
PT3239134T (pt) 2013-01-31 2021-01-28 Vertex Pharma Piridona amidas como moduladores dos canais de sódio
DE102013212933B3 (de) * 2013-07-03 2014-11-27 Schaeffler Technologies Gmbh & Co. Kg Lageranordnung in einem Elektromotor
JP7232815B2 (ja) 2017-08-16 2023-03-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ５，１０－メチレン－（６ｒ）－テトラヒドロ葉酸を含む安定な凍結乾燥物
CN109010273B (zh) * 2018-10-08 2021-03-19 中国药科大学 一种阿哌沙班纳米混悬剂及其制备方法
CN113384526A (zh) * 2021-08-03 2021-09-14 合肥医工医药股份有限公司 一种稳定的阿哌沙班口服溶液制剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3030272A (en) * 1960-05-26 1962-04-17 Abbott Lab Stable heaparin solution
CA2149150C (en) 1992-11-27 2000-08-01 David R. Carver Injectable taxol composition with improved stability
US6080767A (en) 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
SI0906094T1 (en) 1996-01-02 2003-12-31 Aventis Pharmaceuticals Inc. Substituted n- (aminoiminomethyl or aminomethyl)phenyl)propyl amides
GB0108903D0 (en) * 2000-10-05 2001-05-30 Aventis Pharm Prod Inc Novel crystalline forms of a factor Xa inhibitor
US20050059719A1 (en) * 2003-09-16 2005-03-17 Badawy Sherif Ibrahim Farag Solid dosage formulation containing a Factor Xa inhibitor and method
FR2863891B1 (fr) * 2003-12-23 2006-03-24 Pf Medicament Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation
CA2766533A1 (en) * 2009-07-29 2011-02-03 Sanofi Otamixaban for treatment of elderly and renal impaired non-st elevation myocardial infarction patients
SG193612A1 (en) 2011-03-29 2013-11-29 Sanofi Sa Benzoic acid salt of otamixaban
KR101844623B1 (ko) 2011-03-29 2018-04-02 사노피 안정성이 향상된 오타믹사반 제제

Also Published As

Publication number Publication date
EA025572B1 (ru) 2017-01-30
JP5993933B2 (ja) 2016-09-14
SG193932A1 (en) 2013-11-29
ZA201308061B (en) 2015-01-28
IL228573A0 (en) 2013-12-31
MX342324B (es) 2016-09-23
KR20140019818A (ko) 2014-02-17
US20140018398A1 (en) 2014-01-16
CN103561723B (zh) 2016-04-20
CN103561723A (zh) 2014-02-05
CA2830962C (en) 2019-06-18
BR112013024801A2 (pt) 2016-12-20
US9993464B2 (en) 2018-06-12
AU2012234323A1 (en) 2013-10-17
MA35050B1 (fr) 2014-04-03
MX2013011260A (es) 2014-03-27
IL228573A (en) 2017-12-31
NZ616180A (en) 2015-10-30
AR085580A1 (es) 2013-10-09
WO2012130819A1 (en) 2012-10-04
KR101844623B1 (ko) 2018-04-02
CO6801755A2 (es) 2013-11-29
EP2691075A1 (en) 2014-02-05
US20170224668A1 (en) 2017-08-10
JP2014509621A (ja) 2014-04-21
US20120252852A1 (en) 2012-10-04
UY33975A (es) 2012-10-31
CA2830962A1 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
EA201391406A1 (ru) Лекарственные формы отамиксабана с улучшенной стабильностью
EA201500265A1 (ru) Ингибиторы репликации вирусов гриппа
EA201390917A1 (ru) Дигетероарильные соединения в качестве ингибиторов vps34
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
CO6382125A2 (es) Inhibidores de proteína quinasa
EA201201031A1 (ru) Ингибиторы вируса гепатита с
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
EA201391236A1 (ru) Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов
EA201790661A2 (ru) Ингибиторы вируса гепатита c
EA201290860A1 (ru) Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата
EA201790417A2 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
MX338916B (es) Oxazepinas como moduladores del canal de iones.
EA201591195A1 (ru) Новые хинолоновые производные
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201492170A1 (ru) Новые замещенные в цикле n-пиридиниламиды в качестве ингибиторов киназ
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
EA201200472A1 (ru) Сульфонамиды в качестве ингибиторов белков семейства bcl-2, предназначенные для лечения рака
EA201491007A1 (ru) Лекарственные составы
EA201391026A1 (ru) Кристаллическое производное оксазина и его применение в качестве ингибитора bace
BR112014010729A2 (pt) métodos para tratamento de ataques de gota

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU